Ellington Credit Company Prices Offering of Unsecured Notes Mar 25, 2026 9:01 PM Eastern Daylight Time Ellington Credit Company Prices Offering of Unsecured Notes Share The offering is expected to close on March 30, 2026, subject to customary closing conditions. The Fund intends to list the 2031 Notes on the New York Stock Exchange under the symbol "ELLA†. Piper Sandler & Co. is acting as the lead book-running manager for the offering. Lucid Capital Markets LLC and A.G.P./Alliance Global Partners are acti ...

Core Viewpoint - RXO, Inc. is proposing to issue $400 million aggregate principal amount of senior notes due 2031 in a private offering exempt from the registration requirements of the Securities Act of 1933 [1] Group 1: Financial Details - The proposed senior notes will be guaranteed on a senior unsecured basis by the domestic subsidiaries of the Company that are guarantors under the Company's asset-based lending facility [1]

Core Viewpoint - CVR Energy, Inc. plans to offer $1 billion in senior unsecured notes due 2031 and 2034, subject to market conditions [1] Group 1: Offering Details - The offering will be conducted in a private placement under Rule 144A and Regulation S of the Securities Act of 1933 [1] - The notes include $1 billion in aggregate principal amount of senior unsecured notes due 2031 and senior unsecured notes due 2034 [1]

Core Viewpoint - Albertsons Companies, Inc. plans to offer $1,250 million in new senior notes due in 2031 and 2034 to raise capital for its operations [1] Group 1: Financial Details - The total amount of new senior notes being offered is $1,250 million [1] - The notes will be issued in two tranches: the 2031 Notes and the 2034 Notes [1] - Co-issuers of the notes include Safeway Inc., New Albertsons L.P., Albertson's LLC, and Albertsons Safeway LLC [1] Group 2: Use of Proceeds - The company intends to use the net proceeds from the offering for its operational needs [1]

Core Viewpoint - Fortescue Treasury Pty Ltd has announced an increase in its Tender Offers to purchase up to US$750,000,000 of its outstanding notes, up from the previously announced US$600,000,000 [2][12] Group 1: Tender Offer Details - The Tender Offers are aimed at purchasing cash for up to US$750,000,000 aggregate principal amount of its outstanding series of notes [2] - The tender cap for the 2031 Notes has been raised from US$400,000,000 to US$500,000,000 [5] - The aggregate principal amount of the 2031 Notes validly tendered exceeded the new tender cap, leading to a proration factor of approximately 44% for accepted purchases [6] - The aggregate principal amount of the 2030 Notes and 2031 Notes validly tendered exceeded the Aggregate Maximum Tender Amount, resulting in a proration factor of approximately 50% for the 2030 Notes [7] Group 2: Early Tender Results - As of the Early Tender Date, the total principal amount tendered for the 2031 Notes was US$1,136,212,000, while for the 2030 Notes it was US$499,839,000 [4] - Holders of the 2030 Notes accepted for purchase will receive US$1,045.00 per US$1,000.00 principal amount, while those for the 2031 Notes will receive US$978.75 per US$1,000.00 principal amount [10] - The settlement date for the accepted notes is expected to be October 22, 2025 [10] Group 3: Additional Information - The Tender Offers will expire at 5:00 p.m. New York City time on November 4, 2025, unless extended or terminated earlier [11] - BofA Securities has been appointed as the Dealer Manager for the Tender Offers, with D.F. King & Co., Inc. acting as the Tender and Information Agent [13]

Group 1 - Novavax has entered into agreements to issue $225 million of 4.625% Convertible Senior Notes due 2031, which includes approximately $175.3 million in exchange for existing 5.00% Convertible Senior Notes due 2027 and approximately $49.7 million for cash [1][2][9] - The conversion price of the 2031 Notes is set at $11.14 per share, representing a 27.5% premium over the closing price on August 20, 2025 [2] - After the transactions, approximately $26.5 million of the 2027 Notes will remain outstanding, while the total principal amount of the 2031 Notes will be $225 million [2][3] Group 2 - The refinancing extends the maturity date of most existing debt to 2031, improving the capital structure of Novavax [3][9] - The company aims to optimize existing partnerships and expand access to its technology platform through R&D innovation and new collaborations [6]